Synthetic hydrogel nanoparticles for sepsis therapy.
Hiroyuki KoideAnna OkishimaYu HoshinoYuri KamonKeiichi YoshimatsuKazuhiro SaitoIkumi YamauchiSaki AriizumiYuqi ZhouTing-Hui XiaoKeisuke GodaNaoto OkuTomohiro AsaiKenneth J SheaPublished in: Nature communications (2021)
Sepsis is a life-threatening condition caused by the extreme release of inflammatory mediators into the blood in response to infection (e.g., bacterial infection, COVID-19), resulting in the dysfunction of multiple organs. Currently, there is no direct treatment for sepsis. Here we report an abiotic hydrogel nanoparticle (HNP) as a potential therapeutic agent for late-stage sepsis. The HNP captures and neutralizes all variants of histones, a major inflammatory mediator released during sepsis. The highly optimized HNP has high capacity and long-term circulation capability for the selective sequestration and neutralization of histones. Intravenous injection of the HNP protects mice against a lethal dose of histones through the inhibition of platelet aggregation and migration into the lungs. In vivo administration in murine sepsis model mice results in near complete survival. These results establish the potential for synthetic, nonbiological polymer hydrogel sequestrants as a new intervention strategy for sepsis therapy and adds to our understanding of the importance of histones to this condition.
Keyphrases
- septic shock
- acute kidney injury
- intensive care unit
- drug delivery
- oxidative stress
- randomized controlled trial
- coronavirus disease
- type diabetes
- stem cells
- hyaluronic acid
- gene expression
- high fat diet induced
- adipose tissue
- dna methylation
- climate change
- genome wide
- replacement therapy
- arabidopsis thaliana
- respiratory syndrome coronavirus